US 12,440,468 B2
Pharmaceutical compositions of dimethyl fumarate
Sami Karaborni, Cupertino, CA (US); Wei Chen, Cupertino, CA (US); and Suresh Kumar Manthati, Sunnyvale, CA (US)
Assigned to ARBOR PHARMACEUTICALS, LLC, Atlanta, GA (US)
Filed by Arbor Pharmaceuticals, LLC, Atlanta, GA (US)
Filed on Feb. 20, 2024, as Appl. No. 18/582,320.
Application 18/582,320 is a division of application No. 17/551,550, filed on Dec. 15, 2021, granted, now 11,938,111.
Application 17/551,550 is a division of application No. 16/749,427, filed on Jan. 22, 2020, granted, now 11,229,621, issued on Jan. 25, 2022.
Application 16/206,521 is a division of application No. 14/223,026, filed on Mar. 24, 2014, granted, now 10,179,118, issued on Jan. 15, 2019.
Application 16/749,427 is a continuation of application No. 16/206,521, filed on Nov. 30, 2018, granted, now 10,576,055, issued on Mar. 3, 2020.
Claims priority of provisional application 61/805,869, filed on Mar. 27, 2013.
Claims priority of provisional application 61/805,516, filed on Mar. 26, 2013.
Claims priority of provisional application 61/805,137, filed on Mar. 25, 2013.
Claims priority of provisional application 61/804,725, filed on Mar. 24, 2013.
Prior Publication US 2024/0189271 A1, Jun. 13, 2024
Int. Cl. A61K 31/336 (2006.01); A61J 1/03 (2023.01); A61K 31/194 (2006.01); A61K 31/215 (2006.01); A61K 31/225 (2006.01); A61K 31/343 (2006.01); A61K 31/381 (2006.01); A61K 31/403 (2006.01); A61K 9/48 (2006.01)
CPC A61K 31/336 (2013.01) [A61J 1/035 (2013.01); A61K 31/194 (2013.01); A61K 31/215 (2013.01); A61K 31/225 (2013.01); A61K 31/343 (2013.01); A61K 31/381 (2013.01); A61K 31/403 (2013.01); A61K 9/4825 (2013.01)] 12 Claims
 
1. A dosage form for treating multiple sclerosis, comprising:
(a) a therapeutically effective amount of dimethyl fumarate in solid form;
(b) one or more compounds of Formula (V):

OG Complex Work Unit Chemistry
isomers thereof and salts of any of the foregoing, wherein:
each of R13 and R14 is independent chosen from hydrogen and methyl; and wherein the one or more compounds of Formula (V) are present in a combined total amount of about 0.0010% to 2% by weight based on total weight of the dimethyl fumarate; and
(c) a pharmaceutically acceptable vehicle.